JP2024534550A - 抗体の新規組み合わせ及びその使用 - Google Patents

抗体の新規組み合わせ及びその使用 Download PDF

Info

Publication number
JP2024534550A
JP2024534550A JP2024518167A JP2024518167A JP2024534550A JP 2024534550 A JP2024534550 A JP 2024534550A JP 2024518167 A JP2024518167 A JP 2024518167A JP 2024518167 A JP2024518167 A JP 2024518167A JP 2024534550 A JP2024534550 A JP 2024534550A
Authority
JP
Japan
Prior art keywords
antibody molecule
antibody
ctla
tumor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534550A5 (enExample
Inventor
フレンデウス ビョルン
レーン マティルダ
セムリッチ モニカ
モルテンソン リンダ
マルシャン ジャン－バティスト
Original Assignee
バイオインベント インターナショナル アクティエボラーグ
トランジェヌ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオインベント インターナショナル アクティエボラーグ, トランジェヌ ソシエテ アノニム filed Critical バイオインベント インターナショナル アクティエボラーグ
Publication of JP2024534550A publication Critical patent/JP2024534550A/ja
Publication of JP2024534550A5 publication Critical patent/JP2024534550A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024518167A 2021-09-22 2022-09-21 抗体の新規組み合わせ及びその使用 Pending JP2024534550A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21306310.0 2021-09-22
EP21306310 2021-09-22
EP22305050 2022-01-18
EP22305050.1 2022-01-18
PCT/EP2022/076268 WO2023046777A1 (en) 2021-09-22 2022-09-21 Novel combinations of antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024534550A true JP2024534550A (ja) 2024-09-20
JP2024534550A5 JP2024534550A5 (enExample) 2025-09-08

Family

ID=83507478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518167A Pending JP2024534550A (ja) 2021-09-22 2022-09-21 抗体の新規組み合わせ及びその使用

Country Status (10)

Country Link
US (1) US20240374719A1 (enExample)
EP (1) EP4405050A1 (enExample)
JP (1) JP2024534550A (enExample)
KR (1) KR20240067076A (enExample)
AU (1) AU2022351060A1 (enExample)
CA (1) CA3231396A1 (enExample)
IL (1) IL311234A (enExample)
MX (1) MX2024003578A (enExample)
TW (1) TW202321458A (enExample)
WO (1) WO2023046777A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10765710B2 (en) * 2014-07-16 2020-09-08 Institut Gustave-Roussy Combination of oncolytic virus with immune checkpoint modulators
CN120648657A (zh) * 2024-03-08 2025-09-16 上海锦斯生物技术有限公司 一种修饰的溶瘤病毒及其组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
ES2611975T3 (es) 2006-06-20 2017-05-11 Transgene S.A. Procedimiento para producir poxvirus y composiciones de poxvirus
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
US8012738B2 (en) 2007-05-14 2011-09-06 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
BRPI0820576B1 (pt) 2007-11-19 2021-10-19 Transgène S.A. Uso de um poxvírus oncolítico compreendendo um gene i4l e/ou f4l defectivo ou uma composição compreendendo o mesmo
EP2240573A4 (en) 2008-02-12 2011-08-31 Sanofi Pasteur Ltd METHODS OF USING ION EXCHANGE CHROMATOGRAPHY AND DIFFUSION EXCLUSION CHROMATOGRAPHY FOR PURIFYING POXVIRUS
NZ596595A (en) 2009-05-12 2013-05-31 Transgene Sa Method for orthopoxvirus production and purification
ES2813413T3 (es) 2011-08-05 2021-03-23 Sillajen Biotherapeutics Inc Métodos y composiciones para la producción de virus vaccina
MX2019010797A (es) * 2017-03-15 2019-10-24 Amgen Inc Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer.
AU2018254626B2 (en) * 2017-04-21 2023-12-21 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
KR20200131863A (ko) * 2018-03-13 2020-11-24 메모리얼 슬로안 케터링 캔서 센터 암 면역요법을 위한, 면역 관문 차단을 발현하는 종양용해 백시니아 바이러스
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
TW202102543A (zh) * 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
CN111763660A (zh) * 2020-08-07 2020-10-13 南京大学 一种重组溶瘤痘苗病毒及其制备方法和应用

Also Published As

Publication number Publication date
EP4405050A1 (en) 2024-07-31
MX2024003578A (es) 2024-04-03
WO2023046777A1 (en) 2023-03-30
WO2023046777A8 (en) 2023-05-11
KR20240067076A (ko) 2024-05-16
AU2022351060A1 (en) 2024-04-11
IL311234A (en) 2024-05-01
US20240374719A1 (en) 2024-11-14
TW202321458A (zh) 2023-06-01
CA3231396A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
US20230348602A1 (en) Novel anti-pd-1 antibodies
AU2018360800A1 (en) Chimeric antigen receptors specific for B-cell maturation antigen (BCMA)
CN111196852A (zh) 抗tigit抗体及其用途
JP7754506B2 (ja) ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
CN111094982A (zh) 用于治疗和诊断癌症的tim-3拮抗剂
TW202237658A (zh) 抗ｔｎｆｒ２人源化抗體及其用途
EP4445912A1 (en) P329g antibody targeting bcma, combination of same with chimeric antigen receptor cell, and use thereof
CN111108124A (zh) 新型抗体以及treg消耗性抗体和免疫刺激性抗体的组合使用
US20250257135A1 (en) Novel antibodies and nucleotide sequences, and uses thereof
CN115038718A (zh) 抗人程序性死亡配体-1（pd-l1）的抗体及其用途
WO2021155830A1 (en) Anti-hpv t cell receptors and engineered cells
JP2018502068A (ja) 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用
US20240374719A1 (en) Novel combinations of antibodies and uses thereof
TW202328171A (zh) 靶向NKp46之經修飾之IL-2多肽及其用途
WO2021244653A1 (en) Tcr-t cell therapy targeting epstein-barr virus
JP2025526677A (ja) Ｂ７－ｈ３抗原結合性分子
JP2024500511A (ja) 抗ｐｄ－ｌ１抗体及びその使用
HK40106416A (zh) 抗体的新型组合及其用途
CN118176016A (zh) 抗体的新型组合及其用途
JP2026508096A (ja) 治療抗体
HK40115595A (zh) 新颖抗体和核苷酸序列及其用途
CN119661712A (zh) 特异性结合tnfr2的抗体及其应用
HK40095521A (zh) 抗体的新型组合及其用途
CN116963745A (zh) 抗体的新型组合及其用途
BR112018002824B1 (pt) Anticorpo isolado ou um fragmento de ligação, kit, usos do anticorpo e composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250829